|Day Low/High||89.07 / 89.78|
|52 Wk Low/High||73.69 / 89.97|
The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.
Starting August 1, the Lilly Diabetes Solution Center will point people toward customized solutions based on personal circumstances
Even after Monday's rally, these stocks are terrific, says Jim Cramer. Here's how to play the great employment numbers.
This is an opportunity to keep booking profits at what now will be our highest sale price to date.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
In a holiday-shortened week, markets shrugged off trade tariffs, and welcomed a strong jobs report.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CODI, GMRE, HONE, KR, LLY, MJCO, OLP, SBGI, SNX, TBBK Downgrades: CMCM, EDN, GFF, GSM, HGT, SENEA, SENEB, STAA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
OVERCOME Aims to be Largest Study of its Kind With 40,000 People with Migraine
INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018.
INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment...
INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality ™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had...
INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with Emgality ™ (galcanezumab-gnlm).
Study Results Evaluating Humulin R U-500 in Insulet Corporation's Omnipod® U-500™ Insulin Management System Presented at the American Diabetes Association 78th Scientific Sessions
RIDGEFIELD, Conn. and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in...
INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the American...
Data showing improved effectiveness, adherence and persistence to be presented at the ADA's 78th Scientific Sessions®
- In separate analysis, Jardiance (empagliflozin) reduced risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start
INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b...
Data from a Phase 2 trial will be presented for the first time at the ADA's 78th Scientific Sessions®
Markets had a tumultuous week starting with increased trade war fears and ending with a modest oil production increase from OPEC.
INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc.
Pharma firm's new diabetes drug showed positive test results.
INDIANAPOLIS, June 18, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2018 of $0.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.